109 related articles for article (PubMed ID: 27664399)
1. In silico prediction and in vitro and in vivo validation of acaricide fluazuron as a potential inhibitor of FGFR3 and a candidate anticancer drug for bladder carcinoma.
Ke K; Li H; Yao H; Shi XN; Dong C; Zhu Y; Liu X; Li L; Leung KS; Wong MH; Liu XD; Kung HF; Lin MC
Chem Biol Drug Des; 2017 Apr; 89(4):505-513. PubMed ID: 27664399
[TBL] [Abstract][Full Text] [Related]
2. In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug.
Shi XN; Li H; Yao H; Liu X; Li L; Leung KS; Kung HF; Lu D; Wong MH; Lin MC
PLoS One; 2015; 10(7):e0132072. PubMed ID: 26147897
[TBL] [Abstract][Full Text] [Related]
3. Daidzein exerts anti-tumor activity against bladder cancer cells via inhibition of FGFR3 pathway.
He Y; Wu X; Cao Y; Hou Y; Chen H; Wu L; Lu L; Zhu W; Gu Y
Neoplasma; 2016; 63(4):523-31. PubMed ID: 27268915
[TBL] [Abstract][Full Text] [Related]
4. FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.
Acquaviva J; He S; Zhang C; Jimenez JP; Nagai M; Sang J; Sequeira M; Smith DL; Ogawa LS; Inoue T; Tatsuta N; Knowles MA; Bates RC; Proia DA
Mol Cancer Res; 2014 Jul; 12(7):1042-54. PubMed ID: 24784839
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis.
Martínez-Torrecuadrada JL; Cheung LH; López-Serra P; Barderas R; Cañamero M; Ferreiro S; Rosenblum MG; Casal JI
Mol Cancer Ther; 2008 Apr; 7(4):862-73. PubMed ID: 18413799
[TBL] [Abstract][Full Text] [Related]
6. 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest.
Miyake M; Ishii M; Koyama N; Kawashima K; Kodama T; Anai S; Fujimoto K; Hirao Y; Sugano K
J Pharmacol Exp Ther; 2010 Mar; 332(3):795-802. PubMed ID: 19955487
[TBL] [Abstract][Full Text] [Related]
7. Trichlorobenzene-substituted azaaryl compounds as novel FGFR inhibitors exhibiting potent antitumor activity in bladder cancer cells in vitro and in vivo.
Chen CH; Liu YM; Pan SL; Liu YR; Liou JP; Yen Y
Oncotarget; 2016 May; 7(18):26374-87. PubMed ID: 27029060
[TBL] [Abstract][Full Text] [Related]
8. 2-Arylidenedihydroindole-3-ones: design, synthesis, and biological activity on bladder carcinoma cell lines.
Gerby B; Boumendjel A; Blanc M; Bringuier PP; Champelovier P; Fortuné A; Ronot X; Boutonnat J
Bioorg Med Chem Lett; 2007 Jan; 17(1):208-13. PubMed ID: 17049235
[TBL] [Abstract][Full Text] [Related]
9. MMP-1 and Pro-MMP-10 as potential urinary pharmacodynamic biomarkers of FGFR3-targeted therapy in patients with bladder cancer.
Du X; Lin BC; Wang QR; Li H; Ingalla E; Tien J; Rooney I; Ashkenazi A; Penuel E; Qing J
Clin Cancer Res; 2014 Dec; 20(24):6324-35. PubMed ID: 25326231
[TBL] [Abstract][Full Text] [Related]
10. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.
Lamont FR; Tomlinson DC; Cooper PA; Shnyder SD; Chester JD; Knowles MA
Br J Cancer; 2011 Jan; 104(1):75-82. PubMed ID: 21119661
[TBL] [Abstract][Full Text] [Related]
11. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.
Qing J; Du X; Chen Y; Chan P; Li H; Wu P; Marsters S; Stawicki S; Tien J; Totpal K; Ross S; Stinson S; Dornan D; French D; Wang QR; Stephan JP; Wu Y; Wiesmann C; Ashkenazi A
J Clin Invest; 2009 May; 119(5):1216-29. PubMed ID: 19381019
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and structure-activity relationships of pyrimidine derivatives as potent and orally active FGFR3 inhibitors with both increased systemic exposure and enhanced in vitro potency.
Kuriwaki I; Kameda M; Iikubo K; Hisamichi H; Kawamoto Y; Kikuchi S; Moritomo H; Kondoh Y; Terasaka T; Amano Y; Tateishi Y; Echizen Y; Iwai Y; Noda A; Tomiyama H; Nakazawa T; Hirano M
Bioorg Med Chem; 2021 Mar; 33():116019. PubMed ID: 33486159
[TBL] [Abstract][Full Text] [Related]
13. FGFR3 stimulates stearoyl CoA desaturase 1 activity to promote bladder tumor growth.
Du X; Wang QR; Chan E; Merchant M; Liu J; French D; Ashkenazi A; Qing J
Cancer Res; 2012 Nov; 72(22):5843-55. PubMed ID: 23019225
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.
Guagnano V; Furet P; Spanka C; Bordas V; Le Douget M; Stamm C; Brueggen J; Jensen MR; Schnell C; Schmid H; Wartmann M; Berghausen J; Drueckes P; Zimmerlin A; Bussiere D; Murray J; Graus Porta D
J Med Chem; 2011 Oct; 54(20):7066-83. PubMed ID: 21936542
[TBL] [Abstract][Full Text] [Related]
15. FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation.
Azab AK; Azab F; Quang P; Maiso P; Sacco A; Ngo HT; Liu Y; Zhang Y; Morgan BL; Roccaro AM; Ghobrial IM
Clin Cancer Res; 2011 Jul; 17(13):4389-99. PubMed ID: 21521775
[TBL] [Abstract][Full Text] [Related]
16. ETV5 links the FGFR3 and Hippo signalling pathways in bladder cancer.
di Martino E; Alder O; Hurst CD; Knowles MA
Sci Rep; 2019 Apr; 9(1):5740. PubMed ID: 30952872
[TBL] [Abstract][Full Text] [Related]
17. Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder.
Mazzola CR; Siddiqui KM; Billia M; Chin J
Expert Opin Investig Drugs; 2014 Nov; 23(11):1553-62. PubMed ID: 25284004
[TBL] [Abstract][Full Text] [Related]
18. Is interferon gamma one key of metastatic potential increase in human bladder carcinoma?
Champelovier P; Simon A; Garrel C; Levacher G; Praloran V; Seigneurin D
Clin Cancer Res; 2003 Oct; 9(12):4562-9. PubMed ID: 14555531
[TBL] [Abstract][Full Text] [Related]
19. Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity.
Yin Y; Djakovic S; Marsters S; Tien J; Peng J; Tremayne J; Lee G; Neve RM; Wu Y; Merchant M; Ashkenazi A; Carter PJ
Mol Cancer Ther; 2015 Oct; 14(10):2270-8. PubMed ID: 26269606
[TBL] [Abstract][Full Text] [Related]
20. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation.
Martínez-Torrecuadrada J; Cifuentes G; López-Serra P; Saenz P; Martínez A; Casal JI
Clin Cancer Res; 2005 Sep; 11(17):6280-90. PubMed ID: 16144932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]